RPRX
Royalty Pharma plc
$42.36
+$0.68(+1.63%)
70
Overall
100
Value
60
Tech
52
Quality
Market Cap
$16.52B
Volume
3.86M
52W Range
$29.66 - $41.72
Target Price
$47.14
Company Overview
| Mkt Cap | $16.52B | Price | $42.36 |
| Volume | 3.86M | Change | +1.63% |
| P/E Ratio | 19.2 | Open | $41.52 |
| Revenue | $2.3B | Prev Close | $41.68 |
| Net Income | $859.0M | 52W Range | $29.66 - $41.72 |
| Div Yield | 0.94% | Target | $47.14 |
| Overall | 70 | Value | 100 |
| Quality | 52 | Technical | 60 |
No chart data available
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Sector: Manufacturing
Industry: Medicinal and Botanical Manufacturing
Latest News
Citi Sticks to Their Buy Rating for Royalty Pharma (RPRX)
TipRanks Auto-Generated Intelligence Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RPRX | $42.36 | +1.6% | 3.86M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |